zika
viru
zikv
reemerg
mosquitoborn
envelop
viru
belong
genu
flaviviru
genu
recent
receiv
consider
attent
owe
rapidli
increas
incid
dengu
denv
yellow
fever
west
nile
tickborn
enceph
viru
sinc
discoveri
zikv
describ
rel
mild
pathogen
caus
sporad
infect
howev
geograph
distribut
epidem
activ
zikv
infect
increas
dramat
first
larg
outbreak
viru
recent
outbreak
latin
america
largest
zika
outbreak
histori
one
million
case
infect
across
countri
countri
experienc
first
zika
outbreak
sinc
moreov
outbreak
zikv
infect
link
variou
development
neurolog
condit
microcephali
syndrom
rais
seriou
concern
continu
global
prevent
therapeut
product
approv
current
avail
therefor
effect
antivir
vaccin
urgent
need
control
prevent
zikv
infect
understand
human
antibodi
respons
zikv
central
develop
effect
vaccin
threedimension
cryoelectron
microscopi
structur
zikv
reveal
share
high
structur
similar
flavivirus
known
zikv
envelop
e
glycoprotein
found
dimer
surfac
matur
virion
mediat
viral
entri
membran
fusion
serv
major
target
neutral
recent
studi
reveal
critic
target
neutral
antibodi
respons
flavivirus
conform
quaternari
epitop
requir
higherord
structur
present
e
similar
flavivirus
e
protein
zikv
compris
three
domain
central
domain
domain
di
extend
dimer
domain
domain
ii
dii
immunoglobulinlik
domain
domain
iii
diii
previou
studi
denvchalleng
mice
show
diiispecif
antibodi
form
signific
fraction
neutral
antibodi
possess
highli
neutral
intriguingli
found
neutral
human
antibodi
mainli
recogn
quaternari
structuredepend
epitop
present
intact
virion
human
immun
sera
howev
major
antibodi
produc
primari
infect
individu
non
poorli
neutral
antibodi
typic
recogn
fusion
loop
bcloop
dii
e
may
caus
antibodydepend
instanc
preexist
denv
immun
found
highli
crossreact
zikv
potent
increas
subsequ
infect
find
highlight
import
direct
antibodi
specif
zikv
diii
prevent
treat
zikv
infect
number
potent
neutral
monoclon
antibodi
mab
target
zikv
diii
recent
describ
isol
zikvinfect
mice
current
studi
sought
develop
zikv
diiispecif
fulli
human
mab
novel
properti
minim
diverg
germlin
predecessor
chose
recombin
zikv
envelop
diii
antigen
pan
larg
igm
librari
contain
antibodi
construct
blood
healthi
adult
donor
identifi
panel
antibodi
bound
zikv
diii
high
avid
rang
lownanolar
subnanolar
exhibit
weak
moder
neutral
potenc
potent
mab
broadli
neutral
american
asian
zikv
strain
circul
outbreak
combin
anoth
mab
show
synergist
effect
neutral
zikv
vitro
mous
model
zikv
infect
interestingli
bound
adjac
region
diii
loop
repres
recent
identifi
cryptic
epitop
accord
structur
matur
flaviviru
virion
though
cryptic
epitop
specul
intermitt
expos
uncharacter
viru
conform
immunogenet
analysi
suggest
germlinelik
antibodi
ident
germlin
gene
fast
effect
elicit
antibodi
immun
promis
result
may
relev
understand
antigen
epitop
zikv
antibodi
design
effect
zikv
vaccin
serodiagnost
asian
zikv
strain
origin
isol
blood
chines
patient
travel
samoa
obtain
gift
prof
chengfeng
qin
beij
institut
microbiolog
epidemiolog
zikv
strain
flr
obtain
bei
resourc
niaid
nih
bethesda
md
usa
zikv
strain
origin
isol
januari
placenta
human
travel
hondura
isol
blood
human
puerto
rico
decemb
isol
serum
specimen
collect
human
panama
decemb
final
flr
isol
blood
human
barranquilla
colombia
decemb
viru
stock
prepar
inocul
onto
confluent
monolay
vero
cell
mosquito
cell
titrat
plaqueform
unit
pfu
vero
cell
gene
encod
ectodomain
residu
zikv
envelop
protein
diii
zikv
strain
synthes
genewiz
clone
psectag
b
vector
avitag
sequenc
express
vector
confirm
recombin
protein
express
transient
freestyl
cultur
recombin
zikv
diii
protein
purifi
condit
cultur
media
dialyz
phosphatebuff
salin
pb
protein
biotinyl
bira
biotinprotein
ligas
pb
min
ice
add
biotin
coval
avitag
highli
specif
manner
accord
manufactur
instruct
pierc
waltham
usa
larg
phagedisplay
naiv
human
antigenbind
fragment
fab
librari
construct
use
peripher
blood
mononuclear
cell
complementari
dna
healthi
volunt
templat
clone
express
antibodi
gene
repertoir
pan
protocol
essenti
carri
previous
briefli
one
aliquot
frozen
librari
phage
stock
precipit
polyethylen
glycol
peg
nacl
resuspend
pb
recombin
biotinyl
zikv
diiihfc
fusion
protein
use
pan
librari
screen
biotinyl
antigen
util
round
util
round
util
round
util
round
follow
immobil
streptavidinco
magnet
bead
invitrogen
waltham
usa
approxim
phage
particl
use
biopan
phage
librari
preblock
milk
powder
wv
pb
mpb
incub
biotinyl
antigen
mpb
min
incub
streptavidinco
magnet
bead
h
wash
pbst
pb
buffer
supplement
tween
bound
phage
use
infect
midlog
phase
escherichia
coli
bacteria
h
bacteria
grown
yt
medium
contain
ampicillin
wv
glucos
rmin
h
cell
infect
helper
phage
min
room
temperatur
infect
cell
harvest
resuspend
yt
medium
supplement
ampicillin
kanamycin
cell
incub
overnight
rmin
phage
precipit
cultur
supernat
resuspend
steril
pb
next
pan
enrich
antigenspecif
phage
round
pan
assess
polyclon
phage
enzymelink
immunosorb
assay
elisa
posit
clone
express
fab
identifi
third
fourth
round
pan
use
monoclon
phage
elisa
identifi
clone
analyz
classifi
differ
famili
base
aminoacid
sequenc
divers
complementaritydetermin
region
cdr
region
vh
vl
gene
costar
halfarea
highbind
assay
plate
corn
corel
ny
usa
coat
purifi
diiihfc
ngwell
pb
overnight
block
milk
powder
wv
pb
buffer
phage
elisa
phage
round
pan
polyclon
phage
elisa
clone
randomli
pick
third
fourth
round
panninginfect
cell
monoclon
phage
elisa
incub
immobil
antigen
bound
phage
detect
peroxidas
hrp
polyclon
antibodi
pharmacia
piscataway
nj
usa
solubl
fab
bind
assay
serial
dilut
antibodi
ad
incub
h
hrpconjug
mous
antiflag
sigmaaldrich
st
loui
mo
usa
use
detect
bind
capac
wildtyp
mutant
diii
plate
coat
fab
gener
panel
diii
mutant
wildtyp
diii
encod
gene
clone
vector
encod
maltosebind
protein
mbp
result
express
mbp
fusion
protein
mutant
diii
gener
use
sitedirect
mutagenesi
kit
yeasen
inc
shanghai
china
express
e
coli
wildtyp
mutant
diii
incub
hrpconjug
antimbp
neb
inc
ipswich
usa
use
detect
enzym
activ
measur
subsequ
addit
substrat
abt
signal
read
carri
nm
fab
express
perform
e
coli
bacteri
cultur
accord
previous
publish
protocol
purifi
ninta
recombin
fab
carri
flag
tag
ctermini
convers
prepar
heavi
light
chain
fab
amplifi
reclon
vector
protein
express
transient
cultur
purifi
protein
g
column
protein
dialyz
pb
puriti
estim
gel
electrophoresi
protein
concentr
measur
spectrophotometr
zikv
diiihfc
protein
separ
gel
electrophoresi
transfer
onto
nitrocellulos
membran
millipor
billerica
usa
wash
tbst
buffer
mm
trishcl
mm
nacl
membran
block
skim
milk
room
temperatur
h
incub
fab
overnight
wash
tbst
membran
incub
hrpconjug
mous
antiflag
sigmaaldrich
h
room
temperatur
membran
wash
tbst
expos
use
chemiluminesc
detect
kit
cwbio
inc
beij
china
neutral
activ
mab
measur
use
plaqu
reduct
neutral
test
assay
vero
cell
previous
posit
control
mous
sera
produc
immun
mice
recombin
zikv
e
glycoprotein
briefli
mab
dilut
duplic
sixwel
plate
mem
supplement
fetal
calf
serum
equal
volum
zikv
approxim
pfu
ad
incub
h
follow
incub
mixtur
layer
onto
vero
cell
sixwel
plate
incub
h
infect
cell
wash
pb
overlaid
carboxylmethyl
cellulos
incub
day
cell
fix
stain
ml
wv
crystal
violetformaldehyd
solut
plaqu
count
percent
neutral
calcul
base
percent
reduct
plaqu
presenc
absenc
mab
zikv
e
serum
control
bind
kinet
mab
diii
zikv
e
protein
irrelev
protein
influenza
ha
analyz
biolay
interferometri
use
devic
pall
fortebio
menlo
park
ca
usa
purifi
zikvdiiihfc
buffer
sodium
acet
ph
immobil
onto
activ
biosensor
incub
threefold
serial
dilut
antibodi
run
buffer
experi
includ
follow
step
equilibr
activ
carbodiimid
hydrochloridenhydroxysuccinimid
immobil
protein
onto
sensor
quench
ethanolamin
baselin
associ
antibodi
measur
kon
dissoci
antibodi
measur
koff
fit
curv
construct
use
fortebio
data
analysi
softwar
pall
fortebio
competit
assay
solubl
zikvdiiihfc
bound
sensor
associ
mab
nm
measur
secondari
antibodi
nm
ad
presenc
first
mab
aminoacid
sequenc
mab
heavi
lightchain
variabl
domain
vh
vl
independ
align
correspond
primari
sequenc
immunoglobulin
deposit
protein
data
bank
use
swiss
model
websit
best
match
human
germlin
ident
aminoacid
residu
homolog
share
ident
crystal
structur
diii
zikv
e
protein
pdb
identifi
origin
zhao
et
al
describ
initi
model
variabl
domain
gener
base
crystal
structur
chosen
templat
discov
studio
modul
consist
valenc
forc
field
use
add
water
molecul
perform
energi
minim
dock
model
diii
zikv
e
protein
carri
use
zdock
top
optim
complex
consid
structur
represent
color
render
use
pymol
molecular
graphic
system
delano
scientif
san
carlo
ca
usa
background
mice
defici
alphabeta
interferon
receptor
mice
purchas
b
k
univers
group
limit
shanghai
china
hous
specif
pathogenfre
condit
anim
facil
shanghai
public
health
clinic
center
fudan
univers
shanghai
china
mice
transfer
anim
biosafeti
level
laboratori
shanghai
china
infect
antibodi
therapi
zikv
infect
group
mixedsex
mice
use
experi
mice
intraperiton
ip
inject
pfu
zikv
volum
h
post
infect
mice
passiv
transfer
singl
dose
antibodi
cocktail
antibodi
pb
control
via
ip
inject
antibodi
protect
zikv
infect
mice
inocul
cocktail
antibodi
ip
inject
h
mice
infect
pfu
zikv
surviv
weight
loss
diseas
sign
monitor
daili
imgthigh
vquest
version
use
sequenc
annot
assign
v
j
gene
result
imgthigh
vquest
analysi
import
postgresql
databas
structur
queri
languag
use
retriev
data
analysi
experiment
data
analyz
graphpad
prism
softwar
surviv
curv
analyz
logrank
test
weight
loss
compar
use
analysi
varianc
multiplecomparison
test
p
valu
indic
statist
signific
differ
experiment
protocol
approv
institut
committe
fudan
univers
method
carri
accord
relev
guidelin
regul
inform
consent
obtain
subject
previous
prepar
larg
phagedisplay
antibodi
fab
librari
use
peripher
blood
b
cell
nonimmun
healthi
donor
identifi
panel
mab
viral
cancerrel
studi
set
isol
diiispecif
neutral
mab
zikv
use
similar
methodolog
zikv
diii
produc
biotinyl
specif
site
use
target
antigen
biopan
figur
antibodi
select
naiv
human
fab
librari
perform
previous
four
round
pan
potent
enrich
achiev
indic
polyclon
phage
elisa
figur
panel
diiispecif
fab
variou
bind
affin
identifi
use
solubl
expressionbas
monoclon
elisa
figur
among
antibodi
four
uniqu
highbind
clone
select
character
convert
fulllength
human
format
antibodi
reactiv
recombin
diii
e
glycoprotein
western
blot
analys
suggest
mab
might
recogn
linear
epitop
zikv
diii
figur
next
measur
bind
kinet
mab
recombin
diii
protein
use
biolay
interferometri
octetr
pall
fortebio
shown
figur
four
antibodi
exhibit
high
diiibind
avid
equilibrium
dissoci
constant
kd
diii
nm
onrat
kon
per
per
offrat
koff
per
mab
display
bind
pattern
similar
kd
nm
mab
much
faster
offrat
koff
per
respect
slowest
onrat
among
four
mab
kon
per
per
consequ
measur
kd
nm
kd
nm
mab
show
bind
influenza
ha
protein
figur
suggest
bind
could
specif
genet
four
mab
uniqu
vh
vl
sequenc
immunogenet
analysi
sequenc
perform
use
imgt
tool
determin
closest
vh
vl
germlin
gene
figur
tabl
supplementari
figur
analys
germlin
gene
usag
indic
origin
differ
bcell
lineag
furthermor
nucleotid
sequenc
display
ighv
ident
germlin
tabl
somat
mutat
locat
nterminu
antibodi
heavi
chain
posit
far
cdr
region
appear
affect
antigen
bind
figur
supplementari
figur
therefor
four
antibodi
germlinelik
mab
gener
exhibit
lower
immunogen
better
druggabl
properti
compar
somat
hypermut
pattern
vdj
gene
segment
usag
divers
among
four
antibodi
three
share
germlin
gene
slight
differ
allel
variant
interestingli
germlin
vgene
frequent
use
number
human
neutral
mab
isol
individu
infect
flavivirus
includ
west
nile
investig
recombin
frequenc
specif
ighd
ighj
gene
among
germlin
analyz
detail
deep
sequenc
data
antibodyom
studi
naiv
igm
repertoir
healthi
adult
donor
neonat
igm
repertoir
newborn
babi
unpublish
expect
observ
high
recombin
frequenc
variou
ighd
ighj
gene
notabl
uniqu
vh
clone
success
identifi
share
vdj
recombin
pattern
similar
supplementari
figur
thirtythre
uniqu
clone
relat
uniqu
clone
relat
also
identifi
supplementari
figur
contrast
seven
uniqu
clone
relat
antibodi
util
germlin
gene
supplementari
figur
taken
togeth
result
suggest
elicit
germlinelik
antibodi
especi
lineag
antibodi
could
rel
quick
effect
immun
zikv
diiibas
immunogen
examin
neutral
capabl
four
mab
zikv
infect
first
evalu
inhibitori
activ
use
plaqu
reduct
neutral
test
recent
isol
asian
lineag
zikv
zikv
shown
figur
exhibit
highest
neutral
activ
among
four
mab
comparison
modest
neutral
activ
show
evid
neutral
zikv
determin
breadth
neutral
also
test
neutral
activ
panel
repres
circul
zikv
strain
addit
asian
lineag
includ
hondura
strain
puerto
rico
strain
panama
strain
flr
colombia
strain
found
diii
circul
strain
highli
conserv
one
mutat
strain
supplementari
figur
inde
abl
neutral
strain
similar
potenc
suggest
broadli
neutral
antizikv
antibodi
figur
mab
inhibit
zikv
infect
dosedepend
manner
result
neutral
plaqu
reduct
neutral
test
less
effect
control
sera
mice
immun
recombin
zikv
e
glycoprotein
figur
interestingli
neutral
differ
decreas
concentr
figur
suggest
neutral
activ
could
vari
isol
isol
observ
differ
among
four
antibodi
neutral
activ
live
zikv
could
result
differ
bind
avid
recogn
epitop
test
hypothesi
perform
bind
competit
experi
use
biolay
interferometri
biosensor
label
zikv
diii
satur
mab
analyt
solut
follow
addit
second
mab
presenc
first
antibodi
shown
figur
compet
bind
diii
mab
neither
show
competit
three
mab
furthermor
exhibit
much
slower
bind
phase
compar
three
mab
consist
lower
kon
valu
observ
diii
bind
assay
figur
data
reveal
three
distinct
epitop
diii
although
may
recogn
overlap
epitop
much
lower
neutral
activ
could
attribut
lower
diii
bind
avid
taken
togeth
result
suggest
bind
differ
epitop
diii
thu
may
synergist
effect
inhibit
zikv
infect
inde
enhanc
neutral
antibodi
cocktail
combin
detect
compar
either
alon
concentr
indic
moder
synergist
effect
zikv
neutral
figur
previous
develop
molecular
dockingbas
strategi
comput
predict
neutral
antibodi
epitop
receptorbind
domain
merscov
followup
studi
determin
highresolut
complex
structur
antibodi
merscov
receptorbind
domain
xray
crystallographi
found
previou
dock
predict
close
match
crystallograph
geometri
epitop
critic
interact
success
thu
studi
use
similar
approach
map
bind
epitop
neutral
mab
zikv
diii
structur
gener
homolog
model
base
crystal
structur
human
germlin
antibodi
share
aminoacid
sequenc
ident
built
base
anoth
germlin
antibodi
sequenc
structur
energyminim
water
box
dock
onto
crystal
structur
zikv
e
protein
interestingli
found
engag
loop
encompass
c
connect
loop
differ
direct
spatial
locat
figur
shown
figur
epitop
diii
differ
mostli
concentr
loop
residu
respect
result
explain
competit
bind
diii
rel
moder
synergist
effect
use
combin
zikv
neutral
analysi
antibodi
contact
residu
indic
bind
domin
lightchain
cdr
usag
wherea
primarili
use
heavychain
cdr
engag
diii
local
epitop
panel
diii
alanin
scan
mutant
gener
bind
mutant
measur
elisa
substitut
four
residu
loop
could
significantli
reduc
bind
activ
diii
includ
figur
indic
four
residu
involv
epitop
composit
notabl
loop
epitop
recogn
repres
cryptic
epitop
expos
virion
accord
exist
flaviviru
cryoelectron
microscopi
inde
dock
diii
epitop
onto
cryoelectron
microscopi
structur
matur
zikv
virion
found
epitop
buri
insid
access
surfac
figur
interestingli
bind
pattern
zikv
diii
remark
resembl
denv
neutral
antibodi
denv
diii
isol
mous
serum
immun
strain
similarli
loop
epitop
recogn
complet
inaccess
denv
virion
model
therefor
hypothes
cryptic
loop
epitop
could
intermitt
expos
uncharacter
viru
conform
via
process
name
viral
breath
process
antibodi
target
complet
inaccess
epitop
matur
virion
still
neutral
flaviviru
recent
mous
mab
recogn
loop
epitop
also
identifi
immun
therefor
reason
specul
target
uncharacter
virion
structur
moder
neutral
zikv
via
viral
breath
adult
wildtyp
mice
natur
suscept
experiment
infect
recent
develop
lethal
mous
model
zikv
infect
use
mice
defici
receptor
name
mice
success
use
establish
denv
infect
mous
studi
use
model
assess
whether
neutral
mab
could
protect
zikv
infect
vivo
determin
therapeut
potenti
neutral
mab
group
mice
per
group
ip
challeng
pfu
asian
zikv
strain
twelv
hour
later
treat
ip
singl
dose
either
mg
cocktail
mg
pb
control
follow
daili
monitor
wellb
weight
loss
clinic
manifest
mortal
first
day
mice
antibodi
group
significantli
activ
healthier
mice
control
group
day
mice
control
group
suffer
complet
loss
mobil
two
mice
group
one
cocktail
antibodi
group
appear
sign
limb
paralysi
other
appear
healthi
howev
mice
die
within
day
spite
consider
differ
clinic
manifest
antibodi
group
control
group
figur
day
five
six
mice
control
group
surviv
die
three
six
mice
group
surviv
cocktail
antibodi
group
surviv
die
day
mice
control
group
group
die
one
mous
cocktail
antibodi
group
surviv
surviv
last
mous
die
day
evid
neutral
mab
show
therapeut
efficaci
unabl
erad
viru
entir
possibl
moder
neutral
activ
andor
extrem
high
viral
load
anim
model
recent
studi
reveal
ifndefici
mice
highli
suscept
lethal
zikv
therefor
evalu
prophylact
efficaci
mice
inocul
cocktail
antibodi
mg
mg
challeng
ip
h
later
pfu
zikv
strain
instead
pfu
use
therapeut
studi
similar
previou
challeng
pfu
zikv
also
result
mortal
within
day
figur
one
mous
control
group
die
day
three
die
day
surviv
comparison
three
six
mice
cocktail
antibodi
group
die
day
surviv
remain
three
mice
show
sign
limb
paralysi
exhibit
reduc
mobil
albeit
lesser
extent
remain
two
mice
control
group
absenc
significantli
prolong
surviv
treatment
group
could
attribut
high
sensit
ifndefici
mice
zikv
infect
residu
viru
load
could
also
caus
lethal
infect
mice
absenc
complet
neutral
virus
antizikv
mab
interpret
support
recent
find
even
lowest
dose
inoculum
pfu
zikv
viru
result
interestingli
one
studi
mice
receiv
differ
dose
zikv
pfu
die
time
point
mortal
day
consist
current
find
anoth
studi
instead
use
immunedefici
transgen
mice
author
evalu
zikvneutr
mab
wildtyp
mice
treat
mab
mice
exhibit
less
sever
sign
diseas
lower
mortal
compar
ifn
receptor
knockout
dramat
differ
antibodi
group
control
group
would
like
observ
model
explos
epidemiolog
zikv
outbreak
south
america
affect
peopl
previous
record
outbreak
combin
zikv
infect
associ
syndrom
highlight
threat
zikv
global
public
health
signific
progress
made
therapeut
vaccin
current
avail
treat
prevent
diseas
recent
increas
number
mab
emerg
virus
includ
sarscov
merscov
ebola
develop
exhibit
high
potenc
vitro
anim
model
neutral
antibodi
also
play
decis
role
protect
flaviviru
infect
therefor
develop
highaffin
potent
neutral
antibodi
repres
promis
strategi
combat
zikv
exampl
facilit
design
effect
vaccin
capabl
elicit
robust
specif
antibodi
respons
zikv
previou
studi
reveal
two
class
broadli
neutral
antibodi
flavivirus
broadli
neutral
antibodi
target
conserv
fusion
loop
epitop
fle
dii
protein
e
dimer
epitop
ede
one
studi
barbaspaeth
et
describ
panel
denvelicit
antibodi
target
fle
ede
found
ede
antibodi
exhibit
potent
crossneutr
fle
antibodi
indic
ede
antibodi
better
suit
develop
epitopefocus
vaccin
compar
fle
antibodi
induc
poorli
neutral
strongli
infectionenhanc
antibodi
via
antibodydepend
enhanc
howev
fle
immunodomin
epitop
zikv
e
protein
zikvspecif
antibodi
infect
patient
found
fle
therefor
arduou
direct
specif
potent
immun
respons
certain
epitop
diii
without
elicit
crossreact
antibodydepend
enhanc
antibodi
recent
zikv
diiispecif
neutral
mab
isol
demonstr
effici
protect
anim
model
zhao
et
al
report
panel
mab
isol
immun
mice
infecti
zikv
recombin
diii
mab
specif
bound
three
distinct
epitop
diii
effici
inhibit
infect
african
asian
american
zikv
strain
furthermor
mab
target
diii
later
ridg
region
confer
complet
protect
zikvinfect
howev
fulli
human
mab
minim
immunogen
patient
would
prefer
except
isol
neutral
antibodi
infect
vaccin
subject
combinatori
antibodi
librari
phageyeast
displaybas
technolog
revolution
human
antibodi
select
high
bind
activ
novel
herein
biopan
human
fab
librari
zikv
diii
success
select
character
panel
novel
germlinelik
human
mab
high
affin
specif
zikv
diii
first
studi
use
phage
display
screen
identifi
human
antibodi
zikv
four
mab
recogn
three
distinct
epitop
diii
display
function
differ
properti
sinc
germlin
mab
typic
exhibit
good
druggabl
low
immunogen
antibodi
especi
potent
neutral
mab
potenti
develop
antibodybas
therapeut
either
alon
combin
diii
e
proteintarget
human
mab
abil
mab
bind
given
viral
epitop
depend
concentr
affin
interact
infecti
viru
particl
access
epitop
epitop
readili
access
surfac
matur
virion
other
partial
complet
howev
antibodi
recogn
partial
complet
occlud
site
matur
virion
still
neutral
flaviviru
infect
particl
heterogen
respect
matur
andor
dynam
process
known
breath
allow
intermitt
display
cryptic
structur
studi
indic
bind
epitop
loop
diii
access
surfac
matur
virion
instead
like
engag
cryptic
loop
epitop
manner
similar
neutral
mab
residu
loop
intim
involv
later
e
protein
contact
matur
virion
surfac
consequ
exposur
would
requir
substanti
reorgan
particl
perhap
could
occur
local
rather
global
interest
note
identifi
antibodi
studi
share
gene
segment
usag
found
number
human
neutral
mab
isol
flavivirusinfect
individu
also
use
gene
segment
exampl
mab
target
west
nile
target
denv
mab
target
zikv
notabl
gene
frequent
use
number
antivir
antibodi
previous
found
allelespecif
residu
exampl
critic
antigen
bind
viru
structur
studi
warrant
explor
whether
allelespecif
residu
contribut
bind
antibodi
flaviviru
e
protein
structur
function
character
identifi
antibodi
implic
design
effect
zikv
vaccin
e
protein
diii
consid
antigen
choic
vaccin
howev
number
studi
found
use
recombin
flaviviru
diii
subunit
vaccin
elicit
poorli
neutral
antibodi
target
ab
loop
find
suggest
human
antibodi
repertoir
flavivirus
may
actual
direct
away
diiineutr
epitop
especi
epitop
later
ridg
region
diii
recogn
mani
strongest
flavivirusneutr
therefor
diii
subunit
vaccin
among
lead
candid
recent
approv
dengu
vaccin
promin
among
platform
lead
way
zikv
vaccin
result
indic
antibodi
target
cryptic
loop
inher
less
protect
zikv
infect
vitro
vivo
previous
describ
potent
neutral
antibodi
target
upper
later
surfac
diii
although
bind
affin
high
neutral
activ
low
consist
low
neutral
activ
antibodi
modest
protect
mous
model
result
suggest
antibodi
target
cryptic
epitop
diii
zikv
e
protein
probabl
suitabl
therapeut
agent
zikv
human
antibodi
target
loop
also
exist
zikvinfect
patient
current
prioriti
understand
whether
novel
antibodi
contribut
protect
immun
vivo
follow
translat
inform
design
effect
diiibas
vaccin
candid
summari
identifi
panel
human
mab
zikv
diii
sever
bind
distinct
region
diii
dispar
function
activ
defin
previous
unnot
cryptic
loop
epitop
e
protein
diii
studi
implic
develop
effect
zikv
vaccin
